Systems controls are needed to reduce mistaken tests for hemophagocytic lymphohistiocytosis, results of a prospective quality-improvement cohort study.
Clinical Laboratory Services
/ standards
Diagnostic Errors
/ prevention & control
Female
Humans
Lymphohistiocytosis, Hemophagocytic
/ diagnosis
Male
Middle Aged
Needs Assessment
Outcome Assessment, Health Care
Quality Improvement
/ organization & administration
Risk Adjustment
/ methods
Staff Development
/ methods
Time-to-Treatment
/ statistics & numerical data
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
02 Jul 2021
02 Jul 2021
Historique:
received:
15
03
2021
accepted:
10
06
2021
entrez:
30
6
2021
pubmed:
1
7
2021
medline:
9
7
2021
Statut:
ppublish
Résumé
Medical diagnosis and therapy often rely on laboratory testing. We observed mistaken testing in evaluations for hemophagocytic lymphohistiocytosis (HLH) that led to delays and adverse outcomes. Physicians were mistakenly ordering interleukin-2 and quantitative natural killer cell flow cytometry, rather than soluble interleukin 2 receptor (sIL2R) or qualitative natural killer functional tests in the evaluation of patients suspected to have HLH.We initiated a prospective quality improvement project to reduce mistaken testing, reduce delays in correct testing due to mistaken ordering, and improve HLH evaluations. This consisted of provider education, developing an evaluation algorithm, and ultimately required systems interventions such as pop-ups and removal of the mistaken tests from the electronic ordering catalog.Active education reduced mistaken testing significantly in HLH evaluations from baseline (73.3% vs 33.3%, P = .003, relative risk reduction (RRR) 54.5%), but failed to meet the pre-specified RRR cutoff for success (70%). Education alone did not significantly reduce the proportion of HLH evaluations with delays in sIL2R testing (23.3% vs 7.4%, P = .096). Mistaken testing increased after the active intervention ended (33.3% vs 43.5%, P = .390, with RRR 40.7% from baseline. Mistaken test removal was successful: mistaken testing dropped to 0% (P < .001, RRR 100%), saved $14,235 yearly, eliminated delays in sIL2R testing from mistaken testing (23.3% vs 0%, P = .008), and expedited sIL2R testing after admission for HLH symptoms (14.6 days vs 3.8 days, P = .0012). These data show systems controls are highly effective in quality improvement while education has moderate efficacy.
Identifiants
pubmed: 34190181
doi: 10.1097/MD.0000000000026509
pii: 00005792-202107020-00040
pmc: PMC8257870
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e26509Informations de copyright
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no funding and conflicts of interest to disclose.
Références
Schiff GD, Hasan O, Kim S, et al. Diagnostic error in medicine: analysis of 583 physician-reported errors. Arch Intern Med 2009;169:1881–7.
Merrill SA, Naik R, Streiff MB, et al. A prospective quality improvement initiative in adult hemophagocytic lymphohistiocytosis to improve testing and a framework to facilitate trigger identification and mitigate hemorrhage from retrospective analysis. Medicine (Baltimore) 2018;97:e11579.
Gavva C, Johnson M, De Simone N, Sarode R. An audit of thrombophilia testing in patients with ischemic stroke or transient ischemic attack: the futility of testing. J Stroke Cerebrovasc Dis 2018;27:3301–5.
Vrijsen BEL, Naaktgeboren CA, Vos LM, van Solinge WW, Kaasjage HAH, Ten Berg MJ. Inappropriate laboratory testing in internal medicine inpatients: prevalence, causes and interventions. Ann Med Surg (Lond) 2020;51:48–53.
Schram AM, Comstock P, Campo M, et al. Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years. Br J Haematol 2016;172:412–9.
Imashuku S, Kuriyama K, Teramura T, et al. Requirement for etoposide in the treatment of Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol 2001;19:2665–73.
Hicks LK, Bering H, Carson KR, et al. Five hematologic tests and treatments to question. Blood 2014;124:3524–8.
Bindraban RS, van Beneden M, Kramer MHH, et al. Association of a multifaceted intervention with ordering of unnecessary laboratory tests among caregivers in internal medicine departments. JAMA Netw Open 2019;2:e197577.
Henter JI, Horne A, Arico M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48:124–31.
Merrill S, Stevens P, Verschraegen CF, Wood M. Choosing wisely: the utility and costs of routine staging imaging in breast cancer. J Clin Oncol 2015;33:e17800-e.
Kogawa K, Lee SM, Villanueva J, Marmer D, Sumegi J, Filipovich AH. Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood 2002;99:61–6.
Marcenaro S, Gallo F, Martini S, et al. Analysis of natural killer-cell function in familial hemophagocytic lymphohistiocytosis (FHL): defective CD107a surface expression heralds Munc13-4 defect and discriminates between genetic subtypes of the disease. Blood 2006;108:2316–23.
Rubin TS, Zhang K, Gifford C, et al. Perforin and CD107a testing are superior to NK cell function testing for screening patients for genetic HLH. Blood 2017.
Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol 2014;66:2613–20.
Schram AM, Berliner N. How I treat hemophagocytic lymphohistiocytosis in the adult patient. Blood 2015;125:2908–14.
Li J, Wang Q, Zheng W, et al. Hemophagocytic lymphohistiocytosis: clinical analysis of 103 adult patients. Medicine (Baltimore) 2014;93:100–5.
Birndt S, Schenk T, Brunkhorst FM, et al. Hemophagocytic lymphohistiocytosis in adults (aHLH): results from the German HLH registry. Blood 2016;128:2523-.
Ahmed A, Merrill SA, Alsawah F, et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol 2019;6:e630–7.
Imashuku S, Hibi S, Sako M, et al. Soluble interleukin-2 receptor: a useful prognostic factor for patients with hemophagocytic lymphohistiocytosis. Blood 1995;86:4706–7.
Hayden A, Lin M, Park S, et al. Soluble interleukin-2 receptor is a sensitive diagnostic test in adult HLH. Blood Adv 2017;1:2529–34.
May J, Lin C, Martin K, Taylor LJ, Gangaraju R. Thrombophilia testing in hospitalized patients with acute ischemic stroke: an opportunity for hematology input. Blood 2019;134:2105-.
Apostolidou E, Hatami M, Savitz SI, Thomas E, Khatri P, Zha A. Assessment and reduction of unnecessary thrombophilia testing in patients 18–60 years with acute cryptogenic ischemic stroke. Blood 2019;134:3397.
Morris JG, Singh S, Fisher M. Testing for inherited thrombophilias in arterial stroke: can it cause more harm than good? Stroke 2010;41:2985–90.